ARTICLE | Company News
Halozyme endocrine, cancer, dermatology news
October 18, 2010 7:00 AM UTC
The company said it does not expect the moves to have an effect on its cash burn rate. At June 30, Halozyme had $41.3 million in cash and a six-month operating loss of $23.9 million. ...